Review finds possible lycopene intake benefits for blood vessel function in healthy adults
Researchers pooled data from several human studies, but evidence certainty was limited and results depended on study inclusion.
Moderate evidenceReview
Medical disclaimer: This article summarizes research findings and is for informational purposes only. It is not medical advice.
Editorial illustration — not from the study.
The review searched multiple databases and clinical trial registries for human intervention studies where participants consumed lycopene-containing products and researchers measured vascular endothelial function. Most pooled evidence focused on flow-mediated dilation (FMD), a common laboratory/clinical measure related to vascular endothelial function.
Overall, the meta-analysis suggested a favorable effect, but confidence is tempered. The abstract reports that the certainty of evidence was limited and moderate, and the pooled result was no longer statistically significant after excluding one study, indicating the finding may not be robust across all included evidence.
The question reviewed
The researchers asked whether oral lycopene-containing products improve vascular endothelial function in healthy adults, in the context of cardiovascular risk assessment. They included six human intervention studies, and for the main meta-analysis they pooled four trials (continuous intake of at least 7 days) that measured flow-mediated dilation (FMD) (total n = 182).
What the review concluded
In a meta-analysis of four continuous (≥7 days) lycopene-containing product intake studies measuring FMD (n = 182), lycopene intake was associated with a significant increase in FMD (mean difference 1.36, 95% CI 0.20 to 2.51, p = 0.02). The authors reported that the certainty of the evidence across these four studies was limited and moderate. Additionally, one study not included in the meta-analysis found that 15 mg lycopene for 8 weeks increased a reactive hyperemia peripheral arterial tonometry index.
Where this may apply
These findings may apply to people who are broadly similar to the “healthy adults” studied in the included human trials and to situations where outcomes like FMD are used as markers of vascular endothelial function. They do not directly establish effects on cardiovascular disease events, and the results should be treated as suggestive rather than definitive due to limited/moderate certainty and dependence on study inclusion. This review summarizes human evidence, but the abstract does not provide enough detail to know how well the specific lycopene doses, product types, and participant characteristics match every general audience situation.
The significance
Vascular endothelial dysfunction is described in the review as an early marker related to cardiovascular disease risk. If lycopene intake meaningfully improves endothelial function, it could be relevant to how cardiovascular risk is assessed—though this review’s findings are based on measures of function rather than direct cardiovascular outcomes.
Limitations & evidence assessment
Key limitations include the small number of studies and participants in the pooled analysis (four studies, n = 182), with the abstract stating that certainty of evidence was limited and moderate. The authors also report that the pooled finding was no longer statistically significant after excluding one study, suggesting sensitivity to which studies were included. The abstract provides limited detail on the specific interventions, populations beyond “healthy adults,” and the individual study designs/quality, beyond mentioning that risk of bias was assessed.
Why this evidence level: This work is a systematic review and meta-analysis of human intervention studies, which is generally higher-level evidence than single trials. However, the abstract notes limited and moderate certainty across the included studies and that the pooled result became non-significant after excluding one study, which lowers confidence in the overall effect.
Evidence levels are editorial estimates derived from study metadata — they are not clinical appraisals.
This review analyzed human studies comparing two treatments given before surgery for locally advanced esophageal or esophagogastric junction adenocarcinoma: FLOT chemotherapy and CROSS chemoradiotherapy. The pooled estimate favored FLOT for overall survival, but the groups had similar three-year survival, tumor response, surgical margins, and several major perioperative outcomes.
A systematic review examined whether Passiflora edulis, commonly known as passion fruit, is linked with lower blood pressure. It included six preclinical studies and two human trials; the animal and laboratory findings were generally more extensive than the human evidence. The authors reported possible blood-pressure reductions but emphasized that the human studies were small, varied in the extracts used, and short in duration.
Researchers studied 96 people with high-risk, locally advanced rectal cancer in a single-center phase II clinical trial. The treatment combined chemotherapy, short-course radiation, and a targeted drug selected for each study cohort. Overall, 40% had a complete response, but the study did not establish how this approach compares with other treatments.
